Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Vyant Bio Inc | VYNT | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.26 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.26 | 0.26 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.2103 - 0.60 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.26 | USD |
Vyant Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.63M | 6.27M | - | 666k | -22.69M | -3.62 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Vyant Bio News
| Date | Time | Source | News Article |
|---|---|---|---|
| 12/26/2023 | 08:15 | GlobeNewswire Inc. | Vyant Bio Provides Update on Winddown Activities |
| 11/10/2023 | 15:05 | GlobeNewswire Inc. | Vyant Bio Provides Update on Winddown Activities |
| 11/01/2023 | 10:45 | GlobeNewswire Inc. | Vyant Bio Announces Stockholder Approval of Plan of.. |
| 10/24/2023 | 15:00 | GlobeNewswire Inc. | Vyant Bio Announces Completion of StemoniX Asset Sale |
| 10/19/2023 | 10:45 | GlobeNewswire Inc. | Vyant Bio Announces Stockholder Approval of Proposed Asset.. |
| 10/11/2023 | 10:45 | GlobeNewswire Inc. | Vyant Bio Announces 77,522 Votes Needed to Approve Sale of.. |
| 9/28/2023 | 10:45 | GlobeNewswire Inc. | Vyant Bio Announces Adjournment of Special Meeting of.. |
| 9/20/2023 | 12:00 | GlobeNewswire Inc. | Vyant Bio Announces Adjournment of Special Meeting of.. |
| 7/31/2023 | 16:15 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
| 5/12/2023 | 07:00 | GlobeNewswire Inc. | Vyant Bio Announces Last Day of Trading on Nasdaq and Filing.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VYNT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.3087 | 0.60 | 0.2103 | 0.3623186 | 893,156 | -0.0487 | -15.78% |
| 3 Years | 18.25 | 21.175 | 0.2103 | 8.03 | 231,602 | -17.99 | -98.58% |
| 5 Years | 23.00 | 25.60 | 0.2103 | 9.99 | 262,038 | -22.74 | -98.87% |
Vyant Bio Description
| Vyant Bio Inc. Vyant Bio is emerging as an advanced biotechnology drug discovery company. With capabilities in data science both biology and chemistry engineering and regulatory we are rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico in vitro and in vivo modalities. Leveraging these modalities Vyant Bio is able to capitalize on repurposed and novel compounds and then partner with others to further develop and commercialize valuable therapeutics and new treatments for patients. Vyant Bio operates two wholly-owned subsidiaries StemoniX and vivoPharm. Formerly known as Cancer Genetics Inc. the company name was changed to Vyant Bio Inc. in March 2021. Vyant Bio is headquartered in the US with offices in Europe and Australia. |
